For the second time this week, the Netherlands will gain the attention of the pharmaceutical industry, but the latest developments may not please many drug makers.
One day after Amsterdam was chosen as the next home of the European Medicines Agency, the government is readying debate over its pharmaceutical policies, but the session may be hijacked by concerns over high prices and the overall influence of drug makers, according to reports.
About the Author Reprints
